Current Diagnosis & Management of Endometriosis with high risk of Cardiovascular Diseases

In: Archives of Dental and Medical Sciences · 2026 · doi:10.71354/7n80zq59 · W7224099707
Review OA: hybrid CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-31 ⓘ

This review examines the pathophysiological link between endometriosis and cardiovascular disease, highlighting how oxidative stress and treatments like oral contraceptives impact cardiac health to inform safer management strategies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-31 · read from full text ⓘ

This review article examines the pathophysiological links between endometriosis and cardiovascular health, highlighting how chronic inflammation and oxidative stress contribute to endothelial damage and accelerated atherosclerosis in affected patients. The authors note that common treatments for endometriosis, including combined oral contraceptives, COX-2 inhibitors, and definitive surgeries, may further impact cardiac risk profiles, particularly in younger women. Consequently, the paper emphasizes the need for early diagnosis and strategic management strategies that prioritize overall cardiac safety alongside reproductive health outcomes. This paper is centrally about endometriosis — specifically exploring its comorbid relationship with cardiovascular disease and the implications for clinical management.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction: Endometriosis is an enigma when it comes to the theories. It is a chronic gynaecological condition which leads to chronic pelvic pain with heavy menstrual bleed for the patient. Even though it is primarily a gynaecological condition, it has shown to have a connection with cardiovascular health especially due to oxidative stress and chronic inflammation. There has been a decline in cardiovascular health either due to disease process or due to the side effects of the treatment for endometriosis. Methods: There are studies which showed a direct pathophysiological association between cardiac health and endometriosis due to oxidative stress induced damage to endothelial cells, compromised vascular functions and accelerated atherosclerosis. Molecular pathways demonstrate markers which points towards a decline of cardiac health. Result: The impact of treatment of endometriosis has its own impact on the cardiovascular system especially when it is either due to combined oral contraceptives, COX-2 inhibitors or even definitive surgeries in younger patients. Conclusion: Endometriosis and cardiovascular health are intertwined by its shared pathophysiology and management strategies. It is of paramount importance that the overall health is kept in mind while diagnosing and treating endometriosis. Early diagnosis and strategic treatment that are safe for cardiac health for predisposed women are to be considered. A focus on the current development of safer management strategies can be adopted for a more holistic approach to both cardiac and reproductive health.
Full text 11,007 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Introduction: Endometriosis is an enigma when it comes to the theories. It is a chronic gynaecological condition which leads to chronic pelvic pain with heavy menstrual bleed for the patient. Even though it is primarily a gynaecological condition, it has shown to have a connection with cardiovascular health especially due to oxidative stress and chronic inflammation. There has been a decline in cardiovascular health either due to disease process or due to the side effects of the treatment for endometriosis.

Methods

There are studies which showed a direct pathophysiological association between cardiac health and endometriosis due to oxidative stress induced damage to endothelial cells, compromised vascular functions and accelerated atherosclerosis. Molecular pathways demonstrate markers which points towards a decline of cardiac health.

Result

The impact of treatment of endometriosis has its own impact on the cardiovascular system especially when it is either due to combined oral contraceptives, COX-2 inhibitors or even definitive surgeries in younger patients.

Conclusion

Endometriosis and cardiovascular health are intertwined by its shared pathophysiology and management strategies. It is of paramount importance that the overall health is kept in mind while diagnosing and treating endometriosis. Early diagnosis and strategic treatment that are safe for cardiac health for predisposed women are to be considered. A focus on the current development of safer management strategies can be adopted for a more holistic approach to both cardiac and reproductive health. Downloads Article Details Section This work is licensed under a Creative Commons Attribution 4.0 International License. Authors retain copyright and grant the Archives of Dental and Medical Sciences the right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share, copy, distribute, and adapt the work, provided the original authors and source are credited. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. How to Cite

References

Zhang J, Pang M, Li L, Guo C. Global, regional, and national burden of endometriosis among women of reproductive age, 1990-2021: insights from the Global Burden of Disease Study 2021. PLoS One. 2025;20(11):e0337074. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34-41. Cano-Herrera G, Salmun Nehmad S, Ruiz de Chávez Gascón J, Méndez Vionet A, van Tienhoven XA, Osorio Martínez MF, et al. Endometriosis: a comprehensive analysis of the pathophysiology, treatment, and nutritional aspects, and its repercussions on the quality of life of patients. Biomedicines. 2024;12(7):1476. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. World Health Organization. 2025 [cited 2026 Oct 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Lopez EO, Jan A. Cardiovascular disease [Internet]. National Library of Medicine. StatPearls Publishing; 2023 [cited 2026 Oct 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535419/ Garcia M, Mulvagh SL, Bairey Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118(8):1273-1293. Cirillo M, Argento FR, Attanasio M, Becatti M, Ladisa I, Fiorillo C, et al. Atherosclerosis and endometriosis: the role of diet and oxidative stress in a gender-specific disorder. Biomedicines. 2023;11(2):450. Melo AS, Rosa-e-Silva JC, Rosa-e-Silva ACJ de S, Poli-Neto OB, Ferriani RA, Vieira CS. Unfavorable lipid profile in women with endometriosis. Fertility and Sterility. 2010 May;93(7):2433–6. Lamceva J, Uljanovs R, Strumfa I. The main theories on the pathogenesis of endometriosis. Int J Mol Sci. 2023;24(5):4254. Barbieri RL. Stenosis of the external cervical OS: An association with endometriosis in women with chronic pelvic pain. Fertility and Sterility. 1998 Sept;70(3):571–3. D'Hooghe TM, Debrock S. Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Hum Reprod Update. 2002;8(1):84-88. Jungheim ES, Allsworth JE, Jimenez PT, Schon SB, Doblado MA. Early menstrual characteristics and endometriosis: Treloar et al. American Journal of Obstetrics and Gynecology. 2010 June;202(6):660–1. Nnoaham KE, Webster P, Kumbang J, Kennedy SH, Zondervan KT. Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies. Fertil Steril. 2012;98(3):702-712.e6. Wei M, Cheng Y, Bu H, Zhao Y, Zhao W. Length of menstrual cycle and risk of endometriosis: a meta-analysis of 11 case-control studies. Medicine. 2016;95(9):e2922. Marsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated obstructive anomaly. Fertil Steril. 2005;83(3):758-760. S Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. Ann N Y Acad Sci. 2008;1127:106-115. Parag DJ, Vijayanand KM, Lakshmi K. Gastrointestinal deep infiltrative endometriosis with lymph node involvement. Indian Journal of Pathology and Microbiology. 2021 Jan;64(1):213–5. Djokovic D, Calhaz-Jorge C. Somatic stem cells and their dysfunction in endometriosis. Front Surg. 2015;1:51. Hong IS. Endometrial stem/progenitor cells: Properties, origins, and functions. Genes & Diseases [Internet]. 2023 May 1 [cited 2026 Oct 28];10(3):931–47. Available from: https://www.sciencedirect.com/science/article/pii/S2352304222002306 Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14(2):135. Maruyama T. A revised stem cell theory for the pathogenesis of endometriosis. J Pers Med. 2022;12(2):216. Signorile PG, Viceconte R, Baldi A. New insights in pathogenesis of endometriosis. Front Med. 2022;9:879015. Konrad L, Dietze R, Kudipudi PK, Horné F, Meinhold-Heerlein I. Endometriosis in MRKH cases as a proof for the coelomic metaplasia hypothesis? Reproduction. 2019;158(2):R41-R47. Charatsi D, Koukoura O, Ntavela IG, Chintziou F, Gkorila G, Tsagkoulis M, et al. Gastrointestinal and urinary tract endometriosis: a review on the commonest locations of extrapelvic endometriosis. Adv Med. 2018;2018:3461209. Nezhat C, Lindheim SR, Backhus L, Vu M, Vang N, Nezhat A, et al. Thoracic endometriosis syndrome: a review of diagnosis and management. JSLS. 2019;23(3):e2019.00029. Szpila G, Szczotka J, Suchodolski A, Szulik M. Endometriosis and cardiovascular disease: exploring pathophysiological interconnections and risk mechanisms. Diagnostics. 2025;15(12):1458. Marchandot B, Curtiaud A, Matsushita K, Trimaille A, Host A, Faller E, et al. Endometriosis and cardiovascular disease. Eur Heart J Open. 2022;2(1):oeac001. Martins AF, Neto AC, Rodrigues AR, Oliveira SM, Sousa-Mendes C, Leite-Moreira A, et al. Metformin prevents endothelial dysfunction in endometriosis through downregulation of ET-1 and upregulation of eNOS. Biomedicines. 2022;10(11):2782. Pabon MA, Wang X, Rexrode KM. Beyond reproductive health: The cardiovascular risks of endometriosis. European Heart Journal [Internet]. 2024 Sept 24 [cited 2026 Oct 28];. Available from: https://doi.org/10.1093/eurheartj/ehae674 Tani A, Yamamoto S, Maegawa M, Kunimi K, Matsui S, Keyama K, et al. Arterial stiffness is increased in young women with endometriosis. J Obstet Gynaecol. 2015;35(7):711-715. Wellbery C. Diagnosis and treatment of endometriosis. American Family Physician [Internet]. 1999 Oct 15 [cited 2026 Oct 28];60(6):1753–62. Available from: https://www.aafp.org/afp/1999/1015/p1753 Zanelotti A, Decherney AH. Surgery and endometriosis. Clin Obstet Gynecol. 2017;60(3):477-484. Mu F, Rich-Edwards J, Rimm EB, Spiegelman D, Missmer SA. Endometriosis and risk of coronary heart disease. Circ Cardiovasc Qual Outcomes. 2016;9(3):257-264. Kaminski P, Szpotanska-Sikorska M, Wielgos M. Cardiovascular risk and the use of oral contraceptives. Neuro Endocrinol Lett. 2013;34:101-105. Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol. 2016;82(4):957-964. Ikdahl E, Kerola A, Sollerud E, Semb AG. Cardiovascular implications of non-steroidal anti-inflammatory drugs: a comprehensive review, with emphasis on patients with rheumatoid arthritis. Eur Cardiol. 2024;19:e27. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;2015(8):CD011054. Mueck AO. Progestin effects in endometriosis treatment: New research on mechanisms. hmbci. 2010 Dec 1;3(3):469–72. Ferreira RA, Vieira CS, Rosa-e-Silva JC, Rosa-e ACJS, Nogueira AA, Ferriani RA. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010;81(2):117-122. New EP, Mikhail E. A narrative review of using GnRH analogues to reduce endometriosis recurrence after surgery: a double-edged sword. Gynecol Pelvic Med. 2021;4:8. Lim MW, Lucas-Herald AK, Mason A, Delles C, Connelly PJ. Sex differences in the cardiovascular effects of GnRH analogues. J Endocrinol. 2024;261(1). Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28-40. Piróg M, Kacalska-Janssen O, Jach R, Ząbczyk M, Natorska J. Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation. Reproductive BioMedicine Online [Internet]. 2021 Mar 16 [cited 2026 Oct 28];43(1):81–90. Available from: https://www.sciencedirect.com/science/article/pii/S1472648321001097. Ząbczyk M, Ariëns RA, Undas A. Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice. Cardiovasc Res. 2023;119(1):94-111. Pritchard KI, Abramson BL. Cardiovascular health and aromatase inhibitors. Drugs. 2006;66(13):1727–40. Buggio L, Dridi D, Barbara G, Merli CEM, Cetera GE, Vercellini P. Novel pharmacological therapies for the treatment of endometriosis. Expert Review of Clinical Pharmacology. 2022 Aug 30;15(9):1039–52. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-883. Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020;114(1):44-55.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (45)

Source provenance

openalex
last seen: 2026-11-17T06:02:21.439193+00:00
License: CC0 · commercial use OK